NovaBay Pharmaceuticals to Present at the Annual OneMedPlace Finance Forum

By January 7, 2010

NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY), a clinical stage biopharmaceutical company developing a new class of anti-infectives for treating multi-drug resistant pathogens, today announced that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will deliver a corporate presentation at the Annual OneMedPlace Finance Forum on Tuesday, Jan. 12 in San Francisco.

Dr. Najafi’s presentation will take place at 10 a.m. PST in the Cypress Room at the Sir Francis Drake Hotel. His presentation will provide a corporate overview and highlight NovaBay’s clinical progress in its internal programs, as well as in its partnered programs with Alcon (NYSE:ACL) and Galderma.

About NovaBay

NovaBay Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay’s Aganocides are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay™ and Aganocide® are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit:


NovaBay Pharmaceuticals Contacts
Thomas J. Paulson  
Chief Financial Officer
Contact Thomas Paulson

Susan Thomas